Per APA Guidelines, treatment goals for schizophrenia include avoiding relapses and exacerbations that can cause immense negative impact on quality of life (QoL). Long-acting injectables (LAIs) are an effective tool for achieving these goals in both acute and chronic phases of illness; however, there is often reluctance to implement their use. A better understanding of the safety and efficacy of LAIs, particularly in comparison to their oral counterparts, can improve treatment decisions for individual patients.
This CME Outfitters BriefCase guides clinicians through effective strategies to develop and implement a treatment plan based on patient preferences, phase of illness, and the latest evidence on safety and efficacy of LAIs.
At the end of this CME/CE activity, participants should be able to formulate a treatment plan for individuals with schizophrenia that considers patient preferences, acute versus chronic phase of illness, and the latest evidence on long-term safety and efficacy.
The following learning objectives pertain only to those requesting CNE or CPE credit: Identify a treatment plan for individuals with schizophrenia that considers patient preferences, acute versus chronic phase of illness, and the latest evidence on long-term safety and efficacy.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kane reports that he receives grants from Janssen Pharmaceuticals, Inc.; Lundbeck; and Otsuka America Pharmaceutical, Inc. He is a consultant for ACADIA Pharmaceuticals Inc.; Alkermes; Allergan; F. Hoffmann-La Roche; Intra-Cellular Therapies, Inc.; Lundbeck; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals, Inc.; Merck & Co., Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Reviva Pharmaceuticals Inc.; Saladax Biomedical, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He is a stock shareholder of Vanguard Research Group; and LB Pharmaceuticals, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).